Affiliations: Nuclear Medicine, National Research Council CNR and Department of Biomorphological, Functional Sciences University 'Federico II', Naples, Italy
National Cancer Institute, Via M. Semmola, Naples, Italy
References: Bradshaw, D.M., Arceci, R.J., Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (1998) J Clin Oncol, 16, pp. 3674-369
List, A., Non-P-glycoprotein drug export mechanisms of multidrug resistance (1997) Semin Hematol, 34 (SUPPL. 5), pp. 20-24
Chen, C.J., Chin, J.E., Ueda, K., Clark, D.P., Pastan, I., Gottesman, M.M., Roninson, I.B., Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells (1986) Cell, 47, pp. 381-389
Chin, K.V., Pastan, I., Gottesman, M.M., Function and regulation of the human multidrug resistance gene (1993) Adv Cancer Res, 60, pp. 157-180
Van Helvoort, A., Smith, A.J., Sprong, H., Fritzsche, I., Schinkel, A.H., Borst, P., Van Meer, G., MDR 1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine (1996) Cell, 87, pp. 507-517
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M.M., Pastan, I., Willingham, M.C., Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues (1987) Proc Natl Acad Sci USA, 84, pp. 7735-7738
Cordon-Cardo, C., O'Brien, J.P., Casals, D., Rittman-Grauer, L., Biedler, J.L., Melamed, M.R., Bertino, J.R., Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites (1989) Proc Natl Acad Sci USA, 86, pp. 695-698
Borst, P., Schinkel, A.H., Genetic dissection of the function of mammalian P-glycoproteins (1997) TIG, 13, pp. 217-222
Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., Pastan, I., Expression of a multidrug-resistance gene in human tumors and tissues (1987) Proc Natl Acad Sci USA, 84, pp. 265-269
Trock, B.J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR 1/gp 170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Chin, K.V., Ueda, K., Pastan, I., Gottesman, M.M., Modulation of activity of the promoter of the human MDR1 gene by ras and p53 (1992) Science, 255, pp. 459-462
Combates, N.J., Rzepka, R.W., Chen, Y.N., Cohen, D., NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter (1994) J Biol Chem, 269, pp. 29715-29719
Krishnamachary, N., Center, M.S., The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein (1993) Cancer Res, 53, pp. 3658-3661
Breuninger, L.M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S.A., Kruh, G.D., Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution (1995) Cancer Res, 55, pp. 5342-5347
Kruh, G.D., Chan, A., Myers, K., Gaughan, K., Miki, T., Aaronson, S.A., Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene (1994) Cancer Res, pp. 1649-1652
Paulusma, C.C., Kool, M., Bosma, P.J., Scheffer, G.L., Ter Borg, F., Scheper, R.J., Tygat, G.N., Oude Elferink, R.P., A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome (1997) Hepatology, 25, pp. 1539-1542
Borst, P., Kool, M., Evers, R., Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? (1997) Semin Cancer Biol, 8, pp. 205-213
Piwnica-Worms, D., Chiu, M.L., Budding, M., Kronauge, J.F., Kramer, R.A., Croop, J.M., Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex (1993) Cancer Res, 53, pp. 977-984
Crankshaw, C.L., Marmion, M., Luker, G.D., Rao, V., Dahlheimer, J., Burleigh, D., Webb, E., Piwnica-Worms, D., Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein (1998) J Nucl Med, 39, pp. 77-86
Levchenko, A., Metha, M., Lee, J.B., Humm, J.L., Augensen, F., Squire, O., Kothari, P.J., Larson, S.M., Evaluation of 11C-colchicine for PET imaging of multiple drug resistance (2000) J Nucl Med, 41, pp. 493-501
Elsinga, P.H., Franssen, E.J.F., Hendrikse, N.H., Fluks, L., Weemaes, A.A., Van der Graaf, W.T.A., De Vries, E.G.E., Vaalburg, W., Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET (1996) J Nucl Med, 37, pp. 1571-1575
Hendrikse, N.H., DeVries, E.G.E., Eriks-Fluks, L., Van der Graaf, W.T.A., Hospers, G.A.P., Willemsen, A.T.M., Vaalburg, W., Franssen, E.J.F., A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier (1999) Cancer Res, 59, pp. 2411-2416
Ballinger, J.R., Hua, H.A., Berry, B.W., Firby, P., Boxen, I., 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant (1995) Nucl Med Commun, 16, pp. 253-257
Khalkhali, I., Cutrone, J.A., Diggles, L., Minshkin, M., The role of nuclear medicine imaging for the evaluation of patients with breast abnormalities (1996), pp. 113-142. , Freeman LM, ed. Nuclear Medicine Annual 1996 New York
Raven Press LtdAbdel-Dayem, H.M., Scott, A.M., Macapinlac, H.A., El-Grazzar, A.H., Larson, S.M., Role of Thallium-201 Chloride and 99mTc-sestamibi in tumor imaging (1994), pp. 181-234. , Freeman LM, ed. Nuclear Medicine Annual 1994 New York
Raven Press LtdPiwnica-Worms, D., Kronauge, J.F., Chiu, M.L., Uptake and retention of hexakis (2methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mithochondrial and plasma membrane potential dependence (1990) Circulation, 82, pp. 1826-1838
Delmon-Moingeon, L.I., Piwnica-Worms, D., Van den Abbeele, A.D., Holman, B.L., Davison, A., Jones, A.G., Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro (1990) Cancer Res, 50, pp. 2198-2202
Carvalho, P.A., Chiu, M.L., Kronauge, J.F., Kawamura, M., Jones, A.G., Holman, L.B., Piwnica-Worms, D., Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat heart (1992) J Nucl Med, 33, pp. 1516-1522
Ballinger, J.R., Bannerman, J., Boxen, I., Firby, P., Hartman, N.J., Moore, M.J., Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells (1996) J Nucl Med, 37, pp. 1578-1582
Ballinger, J.R., Muzzammil, T., Moore, M.J., Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors (1997) J Nucl Med, 38, pp. 1915-1919
Sikic, B., Pharmacologic approaches to reversing multidrug resistance (1997) Semin Hematol, 34 (SUPPL. 5), pp. 40-47
Moretti, J.L., Azaloux, H., Boisseron, D., Kouyoumdjian, J.C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) Eur J Nucl Med, 23, pp. 980-986
Kostakoglu, L., Elahi, N., Kiratli, P., Ruacan, S., Sayek, I., Balali, E., Sungur, A., Bekdik, C., Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors (1997) J Nucl Med, 38, pp. 1003-1008
Kostakoglu, L., Guc, D., Canpinar, H., Kars, A., Alper, E., Kiratli, P., Hayran, M., Kansu, E., P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy (1998) J Nucl Med, 39, pp. 1191-1197
Pace, L., Catalano, L., Pinto, A.M., De Renzo, A., Di Gennaro, F., Califano, C., Del Vecchio, S., Salvatore, M., Different patterns of technetium-99m sestamibi uptake in multiple myeloma (1998) Eur J Nucl Med, 25, pp. 714-720
Cutrone, J.A., Yospur, L.S., Khalkhali, I., Tolmos, J., Devito, A., Diggles, L., Vargas, M.P., French, S., Immunohistologic assessment of technetium-99-MIBI uptake in benign and malignant breast lesions (1998) J Nucl Med, 39, pp. 449-453
Scopinaro, F., Schillaci, O., Scarpini, M., Mingazzini, P.L., Di Macio, L., Banci, M., Danieli, R., Centi Colella, A., Technetium-99m-sestamibi: An indicator of breast cancer invasiveness (1994) Eur J Nucl Med, 21, pp. 984-987
Del Vecchio, S., Ciarmiello, A., Potena, M.I., Carriero, M.V., Mainolfi, C., Botti, G., Thomas, R., Salvatore, M., In vivo detection of multidrug-resistant (mdr1) phenotype by 99mTc-Sestamibi scan in untreated breast cancer patients (1997) Eur J Nucl Med, 24, pp. 150-159
Taki, J., Sumiya, H., Asada, N., Ueda, Y., Tsuchiya, H., Tonami, N., Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy (1998) J Nucl Med, 39, pp. 1179-1184
Moretti, J.L., Caglar, M., Boaziz, C., Caillat-Vigneron, N., Morere, J.F., Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: Can we predict the response to chemotherapy in small cell lung cancer? (1995) Eur J Nucl Med, 22, pp. 177-180
Dimitrakopoulou-Strauss, Strauss, L.G., Goldschmidt, H., Lorenz, W.J., Maier-Borst, W., Van Kaick, G., Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas (1995) Eur J Nucl Med, 22, pp. 434-442
Kapucu, L.O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukcu, M., Unlu, M., Evaluation of therapy response in children with untrated malignant lymphomas using technetium-99m-Sestamibi (1997) J Nucl Med, 38, pp. 243-247
Ciarmiello, A., Del Vecchio, S., Silvestro, P., Potena, M.I., Carriero, M.V., Thomas, R., Botti, G., Salvatore, M., Tumor clearance of technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer (1998) J Clin Oncol, 16, pp. 1677-1683
Kostakoglu, L., Kiratli, P., Ruacan, S., Hayran, M., Emri, S., Ergun, E., Bekdik, C.F., Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer (1998) J Nucl Med, 39, pp. 228-234
Ota, E., Abe, Y., Oshika, Y., Ozeki, Y., Iwasaki, M., Inoue, H., Yamazaki, H., Nakamura, M., Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer (1995) Br J Cancer, 72, pp. 550-554
Oka, M., Fukuda, M., Sakamoto, A., Takatani, H., Fukuda, M., Soda, H., Kohno, S., The clinical role of MDR1 gene expression in human lung cancer (1997) Anticancer Res, 17, pp. 721-724
Kreisholt, J., Sorensen, M., Jensen, P.B., Nielsen, B.S., Andersen, C.B., Sehested, M., Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer (1998) Br J Cancer, 77, pp. 1469-1473
Savaraj, N., Wu, C.J., Xu, R., Lampidis, T., Lai, S., Donnelly, E., Solomon, J., Feun, L.G., Multidrug-resistant gene expression in small-cell lung cancer (1997) Am J Clin Oncol, 20, pp. 398-403
Giaccone, G., Pinedo, H.M., Scheper, R.J., Flens, M.J., Dingemans, A.M., Broxterman, H.J., Gazdar, A.F., Van Ark-Otte, J., MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lungs (1996) Int J Cancer, 66, pp. 760-767
Sugawara, I., Akiyama, S., Scheper, R.J., Itoyama, S., Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP (1997) Cancer Letters, 112, pp. 23-31
Koukourakis, M.I., Koukourakis, S., Giatromanolaki, A., Skarlatos, J., Georgoulias, V., Karkavitsas, N., Non-small-cell lung cancer functional imaging: Increased hexakis-2-methoxy-isobutyl-isonitrile minor clearance correlates with resistance to cytotoxic treatment (1997) Clin Cancer Res, 3, pp. 749-754
Bom, H.S., Kim, Y.C., Song, H.C., Min, J.J., Kim, J.Y., Park, K.O., Technetium-99m-MIBI uptake in small cell lung cancer (1998) J Nucl Med, 39, pp. 91-94
Yamamoto, Y., Nishiyama, Y., Satoh, K., Takashima, H., Ohkawa, M., Fujita, J., Kishi, T., Tanabe, M., Comparative study of technetium-99m-sestamibi and thallium-201 SPECT in predicting chemotherapeutic response in small cell lung cancer (1998) J Nucl Med, 39, pp. 1626-1629
Sasaki, M., Kuwabara, Y., Ichiya, Y., Yoshida, T., Nakagawa, M., Soeda, H., Sugio, K., Masuda, K., Prediction of the chemosensitivity of lung cancer by 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT (1999) J Nucl Med, 40, pp. 1778-1783
Luker, G.D., Fracasso, P.M., Dobkin, J., Piwnica-Worms, D., Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo (1997) J Nucl Med, 38, pp. 369-372
Chen, C.C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J.A., Bates, S., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi (1997) Clin Cancer Res, 3, pp. 545-552
Persidis, A., Cancer multidrug resistance (1999) Nat Biotechnol, 17, pp. 94-95
Bradshaw, D. M., Arceci, R. J., Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance (1998) J Clin Oncol, 16, pp. 3674-369
Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., Roninson, I. B., Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells (1986) Cell, 47, pp. 381-389
Chin, K. V., Pastan, I., Gottesman, M. M., Function and regulation of the human multidrug resistance gene (1993) Adv Cancer Res, 60, pp. 157-180
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., Pastan, I., Expression of a multidrug-resistance gene in human tumors and tissues (1987) Proc Natl Acad Sci USA, 84, pp. 265-269
Trock, B. J., Leonessa, F., Clarke, R., Multidrug resistance in breast cancer: A meta-analysis of MDR 1/gp 170 expression and its possible functional significance (1997) J Natl Cancer Inst, 89, pp. 917-931
Chin, K. V., Ueda, K., Pastan, I., Gottesman, M. M., Modulation of activity of the promoter of the human MDR1 gene by ras and p53 (1992) Science, 255, pp. 459-462
Combates, N. J., Rzepka, R. W., Chen, Y. N., Cohen, D., NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter (1994) J Biol Chem, 269, pp. 29715-29719
Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S. A., Kruh, G. D., Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution (1995) Cancer Res, 55, pp. 5342-5347
Kruh, G. D., Chan, A., Myers, K., Gaughan, K., Miki, T., Aaronson, S. A., Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene (1994) Cancer Res, pp. 1649-1652
Paulusma, C. C., Kool, M., Bosma, P. J., Scheffer, G. L., Ter Borg, F., Scheper, R. J., Tygat, G. N., Oude Elferink, R. P., A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome (1997) Hepatology, 25, pp. 1539-1542
Crankshaw, C. L., Marmion, M., Luker, G. D., Rao, V., Dahlheimer, J., Burleigh, D., Webb, E., Piwnica-Worms, D., Novel technetium (III) -Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein (1998) J Nucl Med, 39, pp. 77-86
Elsinga, P. H., Franssen, E. J. F., Hendrikse, N. H., Fluks, L., Weemaes, A. A., Van der Graaf, W. T. A., De Vries, E. G. E., Vaalburg, W., Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET (1996) J Nucl Med, 37, pp. 1571-1575
Hendrikse, N. H., DeVries, E. G. E., Eriks-Fluks, L., Van der Graaf, W. T. A., Hospers, G. A. P., Willemsen, A. T. M., Vaalburg, W., Franssen, E. J. F., A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier (1999) Cancer Res, 59, pp. 2411-2416
Ballinger, J. R., Hua, H. A., Berry, B. W., Firby, P., Boxen, I., 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant (1995) Nucl Med Commun, 16, pp. 253-257
Carvalho, P. A., Chiu, M. L., Kronauge, J. F., Kawamura, M., Jones, A. G., Holman, L. B., Piwnica-Worms, D., Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat heart (1992) J Nucl Med, 33, pp. 1516-1522
Ballinger, J. R., Bannerman, J., Boxen, I., Firby, P., Hartman, N. J., Moore, M. J., Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells (1996) J Nucl Med, 37, pp. 1578-1582
Ballinger, J. R., Muzzammil, T., Moore, M. J., Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors (1997) J Nucl Med, 38, pp. 1915-1919
Moretti, J. L., Azaloux, H., Boisseron, D., Kouyoumdjian, J. C., Vilcoq, J., Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression (1996) Eur J Nucl Med, 23, pp. 980-986
Cutrone, J. A., Yospur, L. S., Khalkhali, I., Tolmos, J., Devito, A., Diggles, L., Vargas, M. P., French, S., Immunohistologic assessment of technetium-99-MIBI uptake in benign and malignant breast lesions (1998) J Nucl Med, 39, pp. 449-453
Moretti, J. L., Caglar, M., Boaziz, C., Caillat-Vigneron, N., Morere, J. F., Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: Can we predict the response to chemotherapy in small cell lung cancer? (1995) Eur J Nucl Med, 22, pp. 177-180
Kapucu, L. O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukcu, M., Unlu, M., Evaluation of therapy response in children with untrated malignant lymphomas using technetium-99m-Sestamibi (1997) J Nucl Med, 38, pp. 243-247
Koukourakis, M. I., Koukourakis, S., Giatromanolaki, A., Skarlatos, J., Georgoulias, V., Karkavitsas, N., Non-small-cell lung cancer functional imaging: Increased hexakis-2-methoxy-isobutyl-isonitrile minor clearance correlates with resistance to cytotoxic treatment (1997) Clin Cancer Res, 3, pp. 749-754
Bom, H. S., Kim, Y. C., Song, H. C., Min, J. J., Kim, J. Y., Park, K. O., Technetium-99m-MIBI uptake in small cell lung cancer (1998) J Nucl Med, 39, pp. 91-94
Luker, G. D., Fracasso, P. M., Dobkin, J., Piwnica-Worms, D., Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo (1997) J Nucl Med, 38, pp. 369-372
Chen, C. C., Meadows, B., Regis, J., Kalafsky, G., Fojo, T., Carrasquillo, J. A., Bates, S., Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m-sestamibi (1997) Clin Cancer Res, 3, pp. 545-552
Scintigraphic detection of multidrug resistance in cancer
One of the most extensively studied mechanisms of drug resistance involves the drug efflux pump P-glycoprotein (Pgp). The availability of radiolabeled substrates of Pgp such as 99mTc-MIBI and analogous 99mTc-labeled agents allows the clinical assessment of Pgp function in cancer patients. The consistency of the results from different institutions and trials strongly support the clinical application of this imaging technique for individual tailoring of chemotherapeutic regimens and for designing clinical trials with Pgp modulators.
Scintigraphic detection of multidrug resistance in cancer
No results.
Scintigraphic detection of multidrug resistance in cancer
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote